Posted on 1/8/19
3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear
For the first time in eight years, a new Pfizer (NYSE:PFE) CEO took the stage at the J.P. Morgan Healthcare Conference. Albert Bourla took the reins . . .
Posted on 1/8/19
Bristol-Myers/Celgene: Win-Win Merger
Summary Bristol-Myers agreed to pay a 54% premium to acquire Celgene. Celgene shareholders get an immediate price boost plus the long-term potential to participate in cheap . . .
Posted on 1/8/19
Should Investors Like Bristol-Myers' Buyout of Celgene?
The first big merger of the year has arrived, in the form of a deal for Bristol-Myers Squibb (NYSE:BMY) to swallow Celgene (NASDAQ:CELG). The two are . . .
Posted on 1/8/19
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Healthcare's biggest event of the year is now under way -- the J.P. Morgan Healthcare Conference. Over the past several years, Celgene (NASDAQ:CELG) has traditionally kicked . . .
Posted on 1/8/19
McCann Health Named among Top 10 'Best Places to Work' by Ad Age
McCann Health today was named to Ad Age's 2019 "Best Places to Work" list, ranking ninth among all North American ad agencies, ad tech firms, media . . .
Posted on 1/7/19
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Companies select two clinical-stage bispecific antibodies for ongoing collaborationRegeneron retains full rights to all its other investigational immuno-oncology programs; Sanofi able to independently pursue own immuno-oncology . . .
Posted on 1/7/19
Stelexis Therapeutics Closes $43 million Series A
Stelexis Therapeutics, LLC announced that it closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.
Posted on 1/7/19
AM Best Ranks UnitedHealth Group and Allianz as World’s Largest Insurers
OLDWICK, N.J.--(BUSINESS WIRE)--UnitedHealth Group Incorporated occupied the top spot in AM Best’s ranking of the world’s 25 largest insurance companies for a fourth straight year, with . . .
Posted on 1/7/19
Bioasis Announces Agreement With Leading Pharmaceutical Company
GUILFORD, Conn.--(BUSINESS WIRE)--Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the . . .
Posted on 1/7/19
McKesson and Genpact Expand Their Relationship
SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--McKesson (NYSE:MCK), a leader in healthcare supply chain management solutions and healthcare information technology, and Genpact (NYSE:G), a global professional services . . .
Posted on 1/7/19
Purdue Pharma L.P. and Ocular Therapeutix Announce Initiation of Collaborative Research Activities
STAMFORD, Conn. & BEDFORD, Mass.--(BUSINESS WIRE)--Purdue Pharma L.P. and Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies, . . .
Posted on 1/7/19
Tabula Rasa HealthCare Completes Acquisition of DoseMe
Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that it completed its acquisition
Posted on 1/7/19
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today provides a business update, including confirmation that the company achieved its guidance for full-year 2018; its financial guidance for . . .
Posted on 1/7/19
Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products
Posted on 1/7/19
Advent International To Acquire Majority Stake In Aimbridge Hospitality
Advent International, one of the largest and most experienced global private equity investors, today announced that it has signed a definitive agreement to acquire a majority . . .
Posted on 1/7/19
Celgene: Still Upside Left After Deal?
SummaryYesterday, Bristol-Myers Squibb announced a deal to acquire Celgene. This was biggest deal in the biotech sector in many, many years.While Celgene has rallied over 25% . . .
Posted on 1/7/19
Merck Could Continue Gains As A Defensive Pick, With Growth On Top Of That
SummaryMerck has been one of the best-performing large caps since volatility returned in October.I argue this is the results of prudent strategy and wise use of . . .
Posted on 1/7/19
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Bristol-Myers Squibb (NYSE:BMY) is acquiring Celgene (NASDAQ:CELG) for roughly $74 billion to create a biopharma goliath. The combined company will boast eight billion-dollar blockbuster drugs and . . .
Posted on 1/7/19
Should Celgene Investors Take Bristol's Money and Run?
In 2018, Bristol-Myers Squibb (NYSE:BMY) relied on just two products to drive growth, and the pharma giant's late-stage development pipeline looks like Old Mother Hubbard's cupboards. . . .
Posted on 1/7/19
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
2019 has started off with a bang in the biopharmaceutical industry. On Thursday, Bristol-Myers Squibb (NYSE:BMY) announced that it planned to acquire Celgene (NASDAQ:CELG) in a . . .
Posted on 1/5/19
China SXT Pharmaceuticals Closes IPO
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces, today announced the . . .
Posted on 1/4/19
Angion Completes Equity Financing and Appoints Senior Executives
UNIONDALE, N.Y., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp., a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces . . .
Posted on 1/4/19
Bristol-Myers: Analysis On Celgene Deal
Summary Bristol-Myers announced a $90-billion deal for Celgene, roughly equal to its own valuation. The deal is not really welcomed by investors, which shun mega-merger deals . . .
Posted on 1/4/19
Here’s What Celgene Shareholders Are Getting From Bristol-Myers Squibb
The opportunity to secure potential best-selling drugs before they win FDA approval convinced pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) to acquire biotechnology giant Celgene (NASDAQ:CELG) on Jan. . . .
Posted on 1/4/19
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership
BUFFALO, N.Y., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies . . .

